Navigation Links
Drug Failed to Reduce Heart Attack Risk After Bypass
Date:4/1/2008

MC-1 had no benefit for postoperative stroke, atrial fibrillation or kidney function

TUESDAY, April 1 (HealthDay News) -- Researchers found that giving patients MC-1, a naturally occurring metabolite of vitamin B6, before and after bypass surgery didn't reduce the risk of heart attack or cardiovascular death.

"Coronary artery bypass graft (CABG) surgery is one of the most important therapeutic options for relieving angina and improving survival and quality of life in patients with multi-vessel coronary artery disease," the Duke University scientists wrote. "It is the most commonly performed cardiac surgical procedure in the world, and, in 2005, more than 250,000 CABG procedures were performed in the United States."

But CABG surgery can lead to serious complications such as heart attack, recurrent angina, kidney problems, stroke and death. Previous research suggested that MC-1 may lower the risk of heart attack or death in high-risk patients.

A new phase 3 multi-center, randomized trial of MC-1 included 3,023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass. It found that cardiovascular death or nonfatal heart attack 30 days after surgery occurred in 140 of 1,510 patients (9.3 percent) who received MC-1 and in 133 of 1,486 patients (9.0 percent) who received a placebo.

All-cause death was 1 percent in the MC-1 group and 0.3 percent in the placebo group at four days, and 1.9 percent in the MC-1 group and 1.5 percent in the placebo group at 30 days.

Both groups had similar levels of postoperative stroke, atrial fibrillation, kidney function, and intensive care unit and hospital lengths of stay.

The findings show that "among intermediate- to high-risk patients undergoing CABG surgery, MC-1, 250 mg/d, given immediately before and for 30 days following surgery did not reduce cardiovascular death or nonfatal (heart attack)," the study authors wrote. "Myocardial injury remains a significant problem following CABG surgery. Effective therapies to reduce perioperative morbidity and mortality are needed but remain elusive."

The study was expected to be presented April 1 at the American College of Cardiology annual meeting and was published online in the Journal of the American Medical Association. It was also expected to be published in the April 16 print issue of the journal.

More information

The U.S. National Heart, Lung, and Blood Institute has more about CABG.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, April 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed
2. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
3. Fallout From Failed AIDS Vaccine Could Dampen Research
4. Safe, Green Insecticides Can Reduce Chemical Exposure in Homes and Gardens
5. Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM)
6. Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections
7. Psychological intervention reduces postembolization pain
8. Aspirin Reduces Asthma Risk Among Older Women
9. Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs
10. Low-Fat Dairy Reduces High Blood Pressure Risk
11. Late treatment with letrozole can reduce breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Failed to Reduce Heart Attack Risk After Bypass 
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: